Trial · NCT02993224
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
NCT02993224, Phase 2, Completed, Novartis Pharmaceuticals; results first posted 2021-10-04
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet. Trials, record NCT02993224. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02993224
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
- NCT number
- NCT02993224
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 148 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
- Interventions
- Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT)
- First posted
- 2016-12-15
- Last updated
- 2021-10-04
- Other registries' IDs
- eudract:2016-002282-61
- Results first posted
- 2021-10-04
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) | Week 48 | Number of participants preferring deferasirox FCT or DT as measured by preference questionnaire (item 2) at Week 48. The preference questionnaire was a 3-item questionnaire. At Week 48, the second item of the preference questionnaire asked the patients (or parents of young patients from 2 to 9 years old) which medicine did the patient "like best": "Tablet to dissolve in liquid" (=deferasirox DT), "Film coated tablet" (=deferasirox FCT), "Sprinkle powder on food" (=deferasirox FCT) and "I don't know" (=none of the above). The number of participants who selected each response option for item 2 was assessed. The analysis was performed for participants who answered the item 2 of the preference questionnaire. |
| Secondary | Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Week 28 | Number of participants preferring deferasirox FCT, deferasirox DT or previous iron chelation therapy as measured by preference questionnaire (item 2) at Week 28. The preference questionnaire was a 3-item questionnaire. At Week 28, the second item of this questionnaire asked the patients (or parents of young patients from 2 to 9 years old) which medicine did the patient "like best": "Tablet to dissolve in liquid" (=deferasirox DT), "Film coated tablet (taken once a day)" (=deferasirox FCT), "Sprinkle powder on food" (=deferasirox FCT), "Tablet (taken 3 times a day)" (=previous iron chelation therapy), "Injection" (=previous iron chelation therapy) and "I don't know" (=none of the above). The number of participants who selected each response option for item 2 was assessed. This analysis was performed only for patients who had received iron chelation therapy prior to enrolling in the study and who answered the item 2 of the preference questionnaire. |
| Secondary | Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2) | Week 4 and Week 24 | Number of participants preferring deferasirox DT or previous iron chelation therapy as measured by preference questionnaire (item 2) at Week 4 and 24. The preference questionnaire was a 3-item questionnaire. At Week 4 and 24, the second item of the preference questionnaire asked the patients (or parents of young patients from 2 to 9 years old) which medicine did the patient "like best": "Tablet to dissolve in liquid" (=deferasirox DT), "Tablet (taken 3 times a day)" (=previous iron chelation therapy), "Injection" (=previous iron chelation therapy) and "I don't know" (=none of the above). The number of participants who selected each response option for item 2 was assessed. This analysis was performed only for patients who had received iron chelation therapy prior to enrolling in the study and who answered item 2 of the preference questionnaire. |
| Secondary | Number of Participants Selecting Each Reason for Treatment Preference as Assessed by the Preference Questionnaire at Week 28 and Week 48 | Week 28 and Week 48 | The preference questionnaire was a 3 item questionnaire. The first item asked the patients (or parents of young patients from 2 to 9 years old) which medicine they were taking. The second item asked which of the medicines did the patient "Like best". Finally, the third item asked the patient why he/she preferred the medicine they chose in the second item. The number of participants who selected each response option for item 3 was assessed. Participants could select multiple reasons for treatment preference at each timepoint. |
| Secondary | Percentage of Consumed Tablet Counts During Deferasirox DT and Deferasirox FCT Treatment Periods | Deferasirox DT: From Baseline up to Week 24. Deferasirox FCT: From Week 25 up to Week 48 | The percentage of consumed tablet counts (compliance) was calculated for each treatment period in the core phase: deferasirox DT (period 1) and deferasirox FCT (period 2). Compliance was defined as the total tablet count consumed divided by total tablet count prescribed and multiplied by 100. Total tablet count consumed was calculated as total number of tablets dispensed minus total number of tablets lost/wasted or returned. Total tablet count prescribed was calculated as the number of tablets that the patient should have taken during this period. If a patient did not return the study drug, the compliance was not calculated. |
| Secondary | Change Over Time in Aftertaste Score of Palatability Questionnaire | Week 4, 24, 28 and 48 | The palatability questionnaire consisted of 4 items, three items measuring taste and one item measuring aftertaste. The aftertaste item scored on a 5-point response scale with the response option: Very good = 1, Good = 2, Neither good nor bad = 3, Bad = 4, Very bad = 5. This item offered an additional response option of "no aftertaste". The aftertaste score was calculated among participants who had an aftertaste. Higher aftertaste scores indicated a worse aftertaste. For participants less than (\<) 10 years old, an observer palatability questionnaire was administered. Items and scoring algorithm remained the same as for participants greater than or equal to (≥) 10 years old. Change in aftertaste score over time was assessed |
| Secondary | Change Over Time in Palatability Score of Palatability Questionnaire | Week 4, 24, 28 and 48 | The palatability questionnaire consisted of 4 items, three items measuring taste and one item measuring aftertaste. Among the taste items, first one measured taste on a 5-point response scale. The other two items measured what happened after taking the medicine and how the perceived amount of liquid taken with the medicine was. Responses to these 3 items were combined and converted into a single palatability score using a scoring matrix: each combination of responses on each of 3 items corresponded to a predefined palatability score. E.g. if a participant responded "bad" to item 1, "vomited \<30min" to item 2 and "not enough" to item 3, then the palatability score assigned was 0. This score ranged from 0 to 11; higher scores indicated better palatability. For participants \<10 years old, an observer palatability questionnaire was administered. Items and scoring algorithm were the same as for participants ≥10 years old. Change in palatability score over time was assessed |
| Secondary | Change From Baseline in Adherence Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | The mSICT patient reported outcome (PRO) consisted of 15 items that represented 3 domains: Adherence, Preference, and Concerns. The adherence domain score consisted of 6 adherence items, measured using a 5-point response scale. The adherence score was calculated by summing these 6 items, with scores ranging from 6 to 30. Higher scores indicated worse adherence. For participants \<10 years old, an observer version (ObsRO) was administered. The adherence score remained the same as for participants ≥10 years old. |
| Secondary | Change From Baseline in Preference Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | The mSICT patient reported outcome (PRO) consisted of 15 items that represented 3 domains: Adherence, Preference, and Concerns. The preference/satisfaction domain score consisted of 2 preference/satisfaction items, measured using a 5-point response scale. The preference score was calculated by summing these 2 items, with scores ranging from 2 to 10. Higher scores indicated worse satisfaction. For participants \< 10 years old, an observer version (ObsRO) was administered. Preference score remained the same as for participants ≥ 10 years old. |
| Secondary | Change From Baseline in Concerns Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | The mSICT patient reported outcome (PRO) consisted of 15 items that represented 3 domains: Adherence, Preference, and Concerns. The concerns domain score consisted of 3 items to address any concerns or worries with the medication. All 3 items were measured on a 5-point response scale. The concerns score was calculated by summing the 3 items, with scores ranging from 3 to 15. Higher scores indicated fewer concerns. For participants \< 10 years old, an observer version (ObsRO) was administered. Concerns score remained the same as for participants ≥ 10 years old. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) | Week 48 | Full Analysis Set (FAS): Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Only participants with available data for this outcome measure were included in this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Week 28 | Participants in the FAS \[to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT)\] and who received iron chelation therapy prior to enrolling in the study. Only participants with available data for this outcome measure were included in this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2) | Week 4 and Week 24 | Participants in the FAS \[to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT)\] and who received iron chelation therapy prior to enrolling in the study. Number analyzed signified number of participants with available data for this outcome measure at specified timepoints. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Selecting Each Reason for Treatment Preference as Assessed by the Preference Questionnaire at Week 28 and Week 48 | Week 28 and Week 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Consumed Tablet Counts During Deferasirox DT and Deferasirox FCT Treatment Periods | Deferasirox DT: From Baseline up to Week 24. Deferasirox FCT: From Week 25 up to Week 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure for each treatment period | Percentage of tablet counts | MEAN |
| SECONDARY | Change Over Time in Aftertaste Score of Palatability Questionnaire | Week 4, 24, 28 and 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure at specified timepoints. | Score on a Scale | MEAN |
| SECONDARY | Change Over Time in Palatability Score of Palatability Questionnaire | Week 4, 24, 28 and 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure at specified timepoints. | Score on a Scale | MEAN |
| SECONDARY | Change From Baseline in Adherence Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure at specified timepoints | Score on a scale | MEAN |
| SECONDARY | Change From Baseline in Preference Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure at specified timepoints | Score on a scale | MEAN |
| SECONDARY | Change From Baseline in Concerns Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire | Baseline (week 2 or, if missing, week 3), week 24, 28 and 48 | FAS: Participants to whom study treatment was assigned and who received at least one dose of each study treatment (DT and FCT). Number analyzed signified number of participants with available data for this outcome measure at specified timepoints | Score on a scale | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for deferasirox DT | 10 | Participants | |
| Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for deferasirox FCT | 121 | Participants | |
| Number of Participants Preferring Deferasirox FCT or DT at Week 48 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for none of the above | 3 | Participants | |
| Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for deferasirox DT | 6 | Participants | |
| Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for deferasirox FCT | 60 | Participants | |
| Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for previous iron chelation therapy | 3 | Participants | |
| Number of Participants Preferring Deferasirox FCT, Deferasirox DT or Previous Iron Chelation Therapy at Week 28 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Preference for none of the above | 0 | Participants | |
| Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Week 4 / Preference for deferasirox DT | 57 | Participants | |
| Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Week 4 / Preference for previous iron chelation therapy | 11 | Participants | |
| Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2) | Deferasirox DT Followed by Deferasirox FCT | Week 4 / Preference for none of the above | 2 | Participants |
1 to 10 of 102Source ClinicalTrials.gov
See all 102 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Core Phase - Period 1 | STARTED | Deferasirox DT Followed by Deferasirox FCT | 148 | |
| Core Phase - Period 1 | COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 140 | |
| Core Phase - Period 1 | NOT COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 8 | |
| Core Phase- Period 2 | STARTED | Deferasirox DT Followed by Deferasirox FCT | 140 | |
| Core Phase- Period 2 | COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 136 | |
| Core Phase- Period 2 | NOT COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 4 | |
| Extension Phase | STARTED | Deferasirox DT Followed by Deferasirox FCT | 116 | |
| Extension Phase | COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 80 | |
| Extension Phase | NOT COMPLETED | Deferasirox DT Followed by Deferasirox FCT | 36 |
Source ClinicalTrials.gov
Adverse events147
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Deferasirox DT (Core Phase) | 16 | 148 | |
| other | Diarrhoea | Gastrointestinal disorders | Deferasirox FCT (Core Phase) | 5 | 140 | |
| other | Diarrhoea | Gastrointestinal disorders | Deferasirox FCT (Extension Phase) | 2 | 116 | |
| other | Pyrexia | General disorders | Deferasirox DT (Core Phase) | 7 | 148 | |
| other | Pyrexia | General disorders | Deferasirox FCT (Core Phase) | 8 | 140 | |
| other | Pyrexia | General disorders | Deferasirox FCT (Extension Phase) | 5 | 116 | |
| other | Hepatomegaly | Hepatobiliary disorders | Deferasirox DT (Core Phase) | 8 | 148 | |
| other | Hepatomegaly | Hepatobiliary disorders | Deferasirox FCT (Core Phase) | 0 | 140 | |
| other | Hepatomegaly | Hepatobiliary disorders | Deferasirox FCT (Extension Phase) | 0 | 116 | |
| other | Nasopharyngitis | Infections and infestations | Deferasirox DT (Core Phase) | 6 | 148 |
1 to 10 of 147Source ClinicalTrials.gov
See all 147 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Deferasirox DT (Core Phase) | 0 | 148 |
| Total, all-cause mortality | Deferasirox FCT (Core Phase) | 0 | 140 |
| Total, all-cause mortality | Deferasirox FCT (Extension Phase) | 0 | 116 |
| Total, other adverse events | Deferasirox DT (Core Phase) | 82 | 148 |
| Total, other adverse events | Deferasirox FCT (Core Phase) | 59 | 140 |
| Total, other adverse events | Deferasirox FCT (Extension Phase) | 49 | 116 |
| Total, serious adverse events | Deferasirox DT (Core Phase) | 13 | 148 |
| Total, serious adverse events | Deferasirox FCT (Core Phase) | 6 | 140 |
| Total, serious adverse events | Deferasirox FCT (Extension Phase) | 16 | 116 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02993224
GET https://conductscience.org/api/trials/v1/NCT02993224/results?page=2